ArticleCancers2024

The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.

Mark Ayoub et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.